Data as of .
FMED vs LFSC: which is really different?
FMED and LFSC hold 11% of their weight in the same names, and LFSC returned more over the year.
ETFIQ Off-Index Score: LFSC scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
11% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, FMED and LFSC hold 11% of their money in the same securities at the same weight.
| Holding | FMED | LFSC |
|---|---|---|
| COGENT BIOSCIENCES INC | 2.86% | 7.52% |
| AXSOME THERAPEUTICS INC | 1.58% | 2.84% |
| CYTOKINETICS INC | 1.55% | 3.16% |
| GUARDANT HEALTH INC | 1.39% | 5.51% |
| VIRIDIAN THERAPEUTICS INC | 1.34% | 2.23% |
| WAYSTAR HOLDING CORP | 0.98% | 1.04% |
| INSMED INC | 1.80% | 0.61% |
| MIRUM PHARMACEUTICALS INC | 0.54% | 4.92% |
| SPYRE THERAPEUTICS INC | 0.05% | 6.41% |
| Only in FMED | Only in LFSC |
|---|---|
| UCB SA 4.75% | Travere Therapeutics Inc 7.66% |
| LIFESTANCE HEALTH GROUP INC 4.29% | LivaNova PLC 7.11% |
| DANAHER CORP 3.43% | Corcept Therapeutics Inc 4.79% |
| 10X GENOMICS INC 3.12% | United Therapeutics Corp 4.15% |
| INTUITIVE SURGICAL INC 2.93% | VeraDermics Inc 3.42% |
| ALNYLAM PHARMACEUTICALS INC 2.80% | Savara Inc 3.22% |
| ARGENX SE 2.79% | Nektar Therapeutics 3.14% |
| LEGEND BIOTECH CORP 2.30% | Trevi Therapeutics Inc 3.12% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated May 31, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| FMED | LFSC | FMED | LFSC | FMED | LFSC | |
| 3 months | +21.3% | +8.7% | +19.0 pts | +6.5 pts | +23.7 pts | +11.2 pts |
| 6 months | +32.3% | +36.0% | +14.3 pts | +17.9 pts | +8.0 pts | +11.7 pts |
| 1 year | +28.3% | +53.0% | +11.7 pts | +36.5 pts | +6.5 pts | +31.3 pts |
| 3 years | +39.6% | not published | −38.8 pts | not published | −58.5 pts | not published |
| Since launch | +25.8% | +81.3% | −57.6 pts | +44.3 pts | −78.1 pts | +30.9 pts |
| FMED Fidelity Disruptive Medicine ETF Holds 68 stocks in broad innovation and megatrends, 25% of its weight in S&P 500 companies | LFSC F/m Emerald Life Sciences Innovation ETF Holds 39 stocks in broad innovation and megatrends, 0% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | Fidelity | F/m |
| Theme | Broad innovation and megatrends | Broad innovation and megatrends |
| In the S&P 500 | 25.4% | 0.0% |
| Active share vs the S&P 500 | 97.1% | 100.0% |
| In the Nasdaq-100 | 8.7% | 0.6% |
| Holdings | 68 | 39 |
| Top ten, share of the fund | 31.5% | 54.7% |
| Expense ratio | 0.50% | 0.54% |
| Fee for the differing part | 0.51% | 0.54% |
| Total return, 1 year | +28.3% | +53.0% |
| vs the S&P 500 | +11.7 pts | +36.5 pts |
| vs the Nasdaq-100 | +6.5 pts | +31.3 pts |
| Below its high | −3.8% | −6.8% |
| Net assets | $52m | $105m |
FMED in plain words
By weight, 25% of FMED's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 97%. The top ten holdings are 32% of the fund across 68 positions, as filed for May 31, 2026. Over the year to Sep 18, 2026 the fund returned +28.3% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 11.7 pts.
LFSC in plain words
By weight, 0% of LFSC's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 55% of the fund across 39 positions, as filed for May 31, 2026. Over the year to Sep 18, 2026 the fund returned +53.0% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 36.5 pts. It sits 6.8% below its all-time high of Aug 19, 2026.
Questions people ask
- Do FMED and LFSC hold the same stocks?
- By their latest filings, 11% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, FMED or LFSC?
- FMED has 25% of its weight in S&P 500 names and LFSC has 0%, so LFSC differs more from the index.
- Which is cheaper, FMED or LFSC?
- FMED charges 0.50% a year and LFSC charges 0.54%, so FMED is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, FMED against LFSC, data as of Sep 18, 2026. https://etfiq.com/compare/themes/fmed-vs-lfsc Free to use with attribution; the underlying files are at Open data.